Anzeige
Mehr »
Freitag, 13.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
839 Leser
Artikel bewerten:
(2)

John Stubbington appointed new CEO of Medicover from 1 May 2025

STOCKHOLM, Feb. 12, 2025 /PRNewswire/ -- The Board of Directors of Medicover AB (publ) ("Medicover") today announces that John Stubbington will succeed Fredrik Rågmark as new CEO of the Medicover group from 1 May 2025.

After 30 years with the Medicover group and 25 years as CEO, Fredrik Rågmark will step down from his operational role in Medicover by the end of April 2025 but will remain available to Medicover during 2025.

"On behalf of the board and the company, I would like to thank Fredrik for his exceptional contribution to the development of Medicover and outstanding leadership of Medicover through all these years. Fredrik has been instrumental in the success of Medicover and in developing the company into a leading provider of healthcare and diagnostic services. Furthermore, we have a strong internal successor in John, who has developed the Healthcare Services division with great success," says Fredrik Stenmo, Chairman of the Board.

"I have, together with the board, concluded that this is the right time for the company and for me to step down from the role as CEO. I am extremely proud of the development of Medicover over these years, our people and culture, and persistently driving organic profitable growth. I believe we have a very good successor in John, who has been an important contributor in our successful development," says Fredrik Rågmark, CEO.

John Stubbington, currently COO of Medicover's Healthcare Services division, joined Medicover in 2010. Before joining Medicover, John held various positions within BUPA, the global health insurer, including nine years of working for their International division.

"I am very grateful for the trust from the board and am honored to keep building on the platform that Fredrik and our leadership team has developed over many years. I am looking forward to continuing on our successful journey with the entire Medicover team," says John Stubbington, incoming CEO.

For further information, please contact:
Hanna Bjellquist, Head of Investor Relations
+46 703 033 272
hanna.bjellquist@medicover.com

Fredrik Stenmo, Chairman of the Board
ir@medicover.com

This information is information that Medicover AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 07.15 CET on 12 February 2025.

Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities, laboratories and blood-drawing points and the largest markets are Poland, Germany, Romania and India. In 2023, Medicover had revenue of €1,746 million and more than 45,000 employees. For more information, go to www.medicover.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/medicover/r/john-stubbington-appointed-new-ceo-of-medicover-from-1-may-2025,c4104107

The following files are available for download:

https://mb.cision.com/Main/15662/4104107/3259805.pdf

John Stubbington appointed new CEO of Medicover from 1 May 2025

Cision View original content:https://www.prnewswire.co.uk/news-releases/john-stubbington-appointed-new-ceo-of-medicover-from-1-may-2025-302374402.html

© 2025 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.